Canada markets open in 3 minutes

Aprea Therapeutics, Inc. (APRE)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
5.17-0.15 (-2.82%)
At close: 04:00PM EDT
5.50 +0.33 (+6.38%)
After hours: 04:14PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close5.32
Open5.37
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.06 - 5.37
52 Week Range2.78 - 8.85
Volume6,204
Avg. Volume33,516
Market Cap28.074M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.95
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.67
  • GlobeNewswire

    Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

    Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented ATRN-119, a novel macrocyclic ATR inhibitor, continues to appear safe and well tolerated with no Dose Limiting Toxicities observed in ongoing Phase 1/2a study; preliminary signs of clinical benefit reported; e

  • GlobeNewswire

    Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

    First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in H1 2024. $21.6 million in cash and cash equivalents as of December 31, 2023 Private placement financing in March 2024 raised upfront gross proceeds of approximately $16 million DOYLESTOW

  • GlobeNewswire

    Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

    Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to $34.0 million in total gross proceeds DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on